40 related articles for article (PubMed ID: 17668165)
1. Chemokines as therapeutic targets in renal cell carcinoma.
Reckamp KL; Strieter RM; Figlin RA
Expert Rev Anticancer Ther; 2008 Jun; 8(6):887-93. PubMed ID: 18533798
[TBL] [Abstract][Full Text] [Related]
2. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
3. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
4. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
5. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
6. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
[TBL] [Abstract][Full Text] [Related]
7. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
8. Molecule of the month. Sorafenib.
Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
[No Abstract] [Full Text] [Related]
9. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson TE
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in renal cell carcinoma.
Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
